PainReform (PainReform) Debt-to-Equity : 0.04 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is PainReform Debt-to-Equity?

PainReform's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.06 Mil. PainReform's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.02 Mil. PainReform's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $1.85 Mil. PainReform's debt to equity for the quarter that ended in Mar. 2024 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for PainReform's Debt-to-Equity or its related term are showing as below:

PRFX' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.1 Med: -0.45 Max: 0.04
Current: 0.04

During the past 6 years, the highest Debt-to-Equity Ratio of PainReform was 0.04. The lowest was -1.10. And the median was -0.45.

PRFX's Debt-to-Equity is ranked better than
84.2% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs PRFX: 0.04

PainReform Debt-to-Equity Historical Data

The historical data trend for PainReform's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PainReform Debt-to-Equity Chart

PainReform Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-1.10

0.01

PainReform Quarterly Data
	Dec18	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															-	-	0.01	0.01	0.04

Competitive Comparison of PainReform's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, PainReform's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PainReform's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PainReform's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where PainReform's Debt-to-Equity falls into.

PainReform Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

PainReform's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.056	+	0.03)	/	7.239
	=	0.01

PainReform's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.057	+	0.015)	/	1.848
	=	0.04

PainReform (NAS:PRFX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

PainReform Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of PainReform's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

PainReform (PainReform) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PainReform Ltd (NAS:PRFX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Yigal Alon Street, Tel Aviv, ISR, 6744316

Website

https://www.painreform.com

PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.